about
Lithium in the treatment of bipolar disorder: pharmacology and pharmacogeneticsHospital treatment, mortality and healthcare costs in relation to socioeconomic status among people with bipolar affective disorder.The psychopathology and treatment of bipolar disorder.Lamotrigine for the treatment of bipolar disorder.Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.A review of psychosocial outcome in patients with bipolar disorder.Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.Lithium revisited: savings brought about by the use of lithium, 1970-1991Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care PhysiciansThe phenotypes of bipolar disorder: relevance for genetic investigations.Psychopharmacology of topiramate: from epilepsy to bipolar disorder.Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorderAssessment and treatment of suicide risk in bipolar disorders.The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice.Lithium: a key to the genetics of bipolar disorder.Retrospective analysis of serum valproate levels and need for an antidepressant drug.Pediatric migraine prophylaxis with divalproex.Sociodemographic and Clinical Predictors of Response in Manic Episodes: A Naturalistic, Prospective, Cohort Study.Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
P2860
Q28081249-3D9BC27C-8C87-4ACF-B35E-783ED805B4F1Q30490035-71D47826-12D8-4A0A-8BD2-BC5134F6A790Q33619910-045E3EC6-EDDC-407C-900F-55093C8432BCQ33838950-04BABF52-9DE5-42F5-93FC-7D30DB7B0DE6Q34146222-89579CAB-EBA5-43A7-B64E-FAEBAC1C21F6Q34176007-8AE41FC9-A588-4D2F-85B0-D325F78C0BAEQ34424267-85487D0C-6C7F-4492-9F0B-D53E9D912BBAQ34998798-7CB26D47-4584-41B0-9A74-483D2AB7739DQ35664266-60F017A7-775F-4C0A-8EF9-F192875B3D4DQ36170788-E86E09DB-A545-4AA3-8D89-91CBA86B53C9Q37166152-60225610-D8B0-4BA3-A516-41F7879AE534Q37199024-030B6B65-2E32-4B33-A889-7A6A15C75E7CQ37356508-A67E4090-8E50-41CC-9D65-CB5A0BD914BDQ37375634-DFC4DEFD-9F0F-4097-9F3D-D11DD66C574EQ37402610-CD61900B-687E-448A-B6E2-932B7B87D45CQ43667540-F37A6597-376F-46AA-8A72-1943D49BA7D8Q43773764-FD64EA32-C4AC-427E-9C29-ADD1CF40AFC1Q47105538-13670804-29DD-499C-9CB4-7C242F96B63AQ52656684-CE5E8061-10C6-400B-A9F2-C2F7633BC21A
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Predictors of response to mood stabilizers.
@en
type
label
Predictors of response to mood stabilizers.
@en
prefLabel
Predictors of response to mood stabilizers.
@en
P2093
P1476
Predictors of response to mood stabilizers.
@en
P2093
Calabrese JR
Woyshville MJ
P304
P356
10.1097/00004714-199604001-00004
P407
P433
P577
1996-04-01T00:00:00Z